Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will present an update of the company’s product development programs at 11:30 a.m. ET on Monday, February 9, 2009, at the 11th Annual BIO CEO & Investor Conference in New York City.

The presentation will review Geron’s portfolio of anti-cancer therapies, including its telomerase inhibitor drug (GRN163L) and its telomerase therapeutic vaccine (GRNVAC1). The update will also include information about the company’s human embryonic stem cell (hESC) development programs for spinal cord injury (GRNOPC1) and its second generation cancer immunotherapy (GRNVAC2).

The audio and slide presentation will be available at the following website address: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=**GERC&item_id=2079516. The presentation will be archived for replay at the same address approximately one hour after the live presentation for a period of 90 days.

About Geron

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem (hESC) cell-based therapeutics. The company has received FDA clearance to begin the world’s first human clinical trial of a hESC-based therapy: GRNOPC1 for acute spinal cord injury. For more information, visit www.geron.com.